Overview
Location
Germany, Saxony-Anhalt, Osterwieck
Employees
10001+
Founded date
1999
Mentions in press and media 21
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 11, 2026 | Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles | COMPANY ANNOUNCEMENT When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company. Read Announcement View Product... |
| Jul 24, 2026 | Trump's Generic Drug Tariffs: U.S. Onshoring Push Faces Steep Challenges | U.S. faces major generic drug tariff changes. Trump announced duties up to 200% on imported generics. A two-year window encourages domestic manufacturing. This policy aims to onshore critical drug production. Industry concerns are high. Gen... |
| Jul 22, 2026 | Trump’s generic drug tariffs: What they could mean for medicine prices, manufacturers and supply | Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing. But thin profit margins make tariffs harder to absorb than for branded medicines and and key policy details r... |
| Feb 25, 2026 | Infusion Pump Software Correction: Fresenius Kabi Issues Correction for Ivenix Large Volume Pump Software | This recall involves correcting certain devices and does not involve removing them from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue ... |
| Jan 5, 2026 | Infusion Pump Recall: Fresenius Kabi Removes Ivenix Large Volume Pumps | This recall involves removing certain devices from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it. Affected Product The FDA i... |
| Dec 16, 2025 | Cellular Origins Raises USD 40M in Series A Funding | Cellular Origins, a Cambridge, UK-based company that enables the manufacturing of cell therapies at scale, raised USD 40M in Series A funding. The round was led by Johnson & Johnson, through its corporate venture capital organisation, J... |
| Jun 17, 2025 | Blood Products Administration Set Recall: Fresenius Kabi Removes Large Volume Pump Blood Products Administration Sets due to Incorrect Assembly | This recall involves removing certain devices from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it. Affected Product Product D... |
| May 24, 2025 | Pharmacists stockpile most common drugs on chance of targeted Trump tariffs | Squeezed by insurers and middlemen, independent pharmacists such as Jolley find themselves on the front lines of a tariff storm. Nearly everyone down the line — drugmakers, pharmacies, wholesalers, and middlemen — opposes most tariffs. Slas... |
| Apr 10, 2025 | Helio Fujita joins Mars as Global People & Organization VP for Petcare business | Mars announces Helio Fujita as Global P&O VP for Mars Petcare, Fujita will join the Mars Petcare Leadership Team and global People & Organization Team Recognized HR leader with over 25 years' experience in HR joins from Fresenius Ka... |
Show more
Reviews 0
FAQ about Fresenius Kabi
When was Fresenius Kabi founded?
Fresenius Kabi was founded in 1999.
What has the press written about Fresenius Kabi?
Parsers VC has collected 21 articles mentioning Fresenius Kabi, among them “Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles” (Aug 11, 2026) and “Trump's Generic Drug Tariffs: U.S. Onshoring Push Faces Steep Challenges” (Jul 24, 2026).
Is Fresenius Kabi still active?
Yes, Fresenius Kabi is active; its latest activity on Parsers VC dates from Oct 8, 2026.